公开(公告)号：US11344540B2

公开(公告)日：2022-05-31

申请号：US16078409

申请日：2017-02-20

Applicant: Novartis AG

Inventor： Bryan Laffitte ,  Michael Badman ,  Jin Chen ,  Sam Lindgren

IPC: A61K31/46 ,  A61P1/12 ,  A61K31/506 ,  A61K31/497 ,  A61K31/4748 ,  A61K47/54 ,  A61P1/16 ,  A61K9/00

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.

公开(公告)号：US11229634B2

公开(公告)日：2022-01-25

申请号：US16078403

申请日：2017-02-17

Applicant: Novartis AG

Inventor： Bryan Laffitte ,  Michael Badman ,  Jin Chen ,  Sam Lindgren

IPC: A61K31/46 ,  A61P1/12 ,  A61K31/497 ,  A61K31/506 ,  A61K31/4748 ,  A61K47/54 ,  A61P1/00 ,  A61K9/00

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver and gastrointestinal diseases.

公开(公告)号：US11110083B2

公开(公告)日：2021-09-07

申请号：US16078431

申请日：2017-02-20

Applicant: Novartis AG

Inventor： Bryan Laffitte ,  Michael Badman ,  Jin Chen ,  Sam Lindgren

IPC: A61K31/46 ,  A61P1/16 ,  A61K31/506 ,  A61K31/497 ,  A61K31/4748 ,  A61K9/00

Abstract: The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases and disorders.

公开(公告)号：US11052069B2

公开(公告)日：2021-07-06

申请号：US16333030

申请日：2017-09-12

Applicant: NOVARTIS AG

Inventor： Bryan Laffitte ,  Andreas Bauer ,  Michael Badman ,  Jin Chen ,  Patrick Mueller ,  Rachel Soon

IPC: A61K31/4162 ,  A61K31/4178 ,  A61P1/16 ,  A61K9/00 ,  A61K31/55 ,  A61K45/06

Abstract: The invention provides novel regimens of farnesoid X receptor (FXR) agonist and methods for modulating the activity of farnesoid X receptors (FXRs) using novel regimes of specific FXR agonists, in particular for treating or preventing fibrotic or cirrhotic diseases or disorders, such as liver diseases.